PMID- 36309386
OWN - NLM
STAT- MEDLINE
DCOM- 20221101
LR  - 20221221
IS  - 1791-7549 (Electronic)
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 36
IP  - 6
DP  - 2022 Nov-Dec
TI  - Study of Therapeutic Effects of Losartan for Sarcopenia Based on the F344xBN Rat 
      Aging Model.
PG  - 2740-2750
LID - 10.21873/invivo.13010 [doi]
AB  - BACKGROUND/AIM: Sarcopenia is an age-related disease in which muscle mass and 
      strength are markedly reduced. There are few effective treatments, but the 
      angiotensin II receptor antagonist losartan has been reported to be effective. 
      Our aim was to evaluate the therapeutic effectiveness of losartan for sarcopenia 
      and explore the underlying mechanisms. MATERIALS AND METHODS: We investigated 
      body weight, muscle mass (gastrocnemius, soleus, peroneus longus, and tibialis 
      anterior muscles), and serum markers in an aged rat model population divided into 
      four treatment groups: Control, exercise, losartan, and exercise plus losartan. 
      The rats were sacrificed at 6, 12, or 18 months after the start of the experiment 
      and autopsies were performed. RESULTS: Compared with the control group, average 
      muscle mass and weight increased in the two groups treated with losartan. AKT 
      serine/threonine kinase (AKT) and extracellular signal-regulated kinase (ERK) 
      muscle growth factors increased in the peroneus longus. mechanistic target of 
      rapamycin kinase (mTOR) increased in tibialis anterior, peroneus longus, and 
      soleus. CONCLUSION: Losartan treatment slowed muscle degeneration and activated 
      the PI3K-AKT-mTOR and ERK/mitogen-activated protein kinase signalling pathways 
      required for production of muscle growth factors when combined with exercise.
CI  - Copyright (c) 2022, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kang, Donghun
AU  - Kang D
AD  - Department of life Science, College of BioNano Technology, Gachon University, 
      Gyeonggi-do, Republic of Korea.
FAU - Park, Kideok
AU  - Park K
AD  - Department of Rehabilitation Medicine, Gachon University, Gil Medical Center 
      Incheon, Incheon, Republic of Korea.
FAU - Kim, Daeyoung
AU  - Kim D
AD  - Department of life Science, College of BioNano Technology, Gachon University, 
      Gyeonggi-do, Republic of Korea davekim@gachon.ac.kr.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - JMS50MPO89 (Losartan)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Rats
MH  - Animals
MH  - *Sarcopenia/drug therapy
MH  - Losartan/pharmacology/metabolism/therapeutic use
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Muscle, Skeletal/pathology
MH  - Aging
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - *Muscular Diseases
MH  - TOR Serine-Threonine Kinases/metabolism
PMC - PMC9677788
OTO - NOTNLM
OT  - PI3K/AKT/mTOR signalling pathway
OT  - Sarcopenia
OT  - aging
OT  - angiotensin II receptor blockade
OT  - exercise
OT  - skeletal muscle
COIS- There are no conflicts to declare.
EDAT- 2022/10/30 06:00
MHDA- 2022/11/02 06:00
PMCR- 2022/11/03
CRDT- 2022/10/29 20:42
PHST- 2022/08/18 00:00 [received]
PHST- 2022/09/17 00:00 [revised]
PHST- 2022/09/26 00:00 [accepted]
PHST- 2022/10/29 20:42 [entrez]
PHST- 2022/10/30 06:00 [pubmed]
PHST- 2022/11/02 06:00 [medline]
PHST- 2022/11/03 00:00 [pmc-release]
AID - 36/6/2740 [pii]
AID - 10.21873/invivo.13010 [doi]
PST - ppublish
SO  - In Vivo. 2022 Nov-Dec;36(6):2740-2750. doi: 10.21873/invivo.13010.